Page 10 - AUQ2022Abstracts

RÉSUMÉS AUQ 2022

Session scientifique IV
Vendredi 28 octobre 2022

Impact of urethral catheterization on voiding efficiency in children Methods: C3H syngeneic mice were injected subcutaneously with MBT-2
Ioana Fugaru , Marika Edvi , Lina di Re , Roman Jednak , Mohammed mouse bladder tumor cells. Prebiotics and control water were gavaged
1
1
1
1
El-Sherbiny , Lysanne Campeau , John-Paul Capolicchio 1 daily until the end of experiment. Following tumor implantation, mice
1
2
1 Division of Pediatric Urology, Department of Pediatric Surgery, Montreal were treated with four injections of anti-PD1 monoclonal antibody or iso-
Children’s Hospital, McGill University, Montreal, QC, Canada, Division type control intraperitoneally. Tumor growth was monitored twice a week.
2
of Urology, Department of Surgery, Jewish General Hospital, McGill Fecal samples were collected at many timepoints during tumor growth for
University, Montreal, QC, Canada the profiling of gut microbiota. Endpoint tumors were dissociated for flow
Introduction: In adults, the presence of a urethral catheter during the void- cytometry analysis of tumor-infiltrating lymphocyte composition.
ing phase decreases the maximal urine flow (Qmax) compared to the free Results: The treatment with prebiotics induced an enrichment of
flow produced during uroflowmetry (UF). Little is known about the effect of Akkermansia and Bifidobacterium bacteria previously associated with
catheterization during Pressure-flow study (PFS) on the Qmax in children, response to ICB therapy. Independently of immunotherapy, two prebiot-
whose urethra is smaller than that of adults. The objective of this study was ics induced a strong anti-tumor activity compared to control group and
to determine the effect of urethral catheterization on Qmax and other void- improved the overall survival of mice. Interestingly, one prebiotic combined
ing parameters during PFS compared to the free flow produced during UF. with anti-PD1 immunotherapy also enhanced the systemic anti-tumor effect
Methods: We retrospectively reviewed the charts of 63 consecutive children of ICB. Underlying mechanisms linking prebiotics treatment with tumor
who underwent UF and PFS at our center in the same setting between 2019 reduction will be deciphered by the flow cytometry analysis and tumor
and 2022. The patients first undergo a UF with full bladder, then PFS after RNA sequencing.
insertion of a 6, 7, or 9 Fr urethral catheter. We excluded patients who Conclusions: Overall, our findings support that promising prebiotics can
were known or investigated for urethral pathologies, who were on clean induce an anti-tumor effect at steady state, and in combination with anti-
intermittent catheterization, and those with major comorbidities. Data was PD-1 treatment, in a BCa mouse model. These data will have a significant
collected from the UF and the PFS and compared using paired t-test. impact to enhance the clinical response to ICB treatment for BCa patients.
Results: Median age at the time of the study was 7 (IQR 5–11). Twenty-one
(39.6%) patients were male and 32 (60.4%) patients were female. Of the Fiabilité et validité de la version franco-Canadienne du Score des
53 patients, three boys and four girls (n=7, 13.2%) were unable to void Symptômes de la Vessie Neurogène
with the catheter during PFS but able to void after its removal. The Qmax Jonathan Fadel , Mahukpe Narcisse Ulrich Singbo , Marie-Pier Deschênes-
1
1
during PFS was 5 mL/s slower than the Qmax recorded on the UF without Rompré , Michel Bureau , Geneviève Nadeau 1
1
1
catheter, representing a decrease of 29% (12.3 vs. 17.3 mL/s, p<0.0001). 1 CHU de Québec - Université Laval, Quebec, QC, Canada
The impact of urethral catheter during PFS was more significant in males Introduction : Le Score des Symptômes de la Vessie Neurogène (SSVN)
vs. females (Qmax decreased by 7.7 vs. 3.3 mL/s, or 45 vs. 19%). There est un questionnaire validé, qui mesure les symptômes vésicaux selon 3
was no statistically significant difference between the residual volumes domaines : l’incontinence, le remplissage et la miction, les conséquences
when comparing PFS to UF (30 vs. 25 mL, p=0.5774). When using age et une question sur la qualité de vie urinaire. Nous visons à valider une
and gender-specific nomograms for Qmax vs. volume voided, we noted version franco-canadienne du SSVN pour les patients atteints de sclérose
that 16/36 (35%), fell from >10 percentile in UF values to 5 percentile en plaques (SEP) ou de lésions de la moelle épinière (LME).
th
th
with the PFS values. Méthodes : Dans cette étude prospective, 107 patients atteints de SEP et
Conclusions: We conclude that Qmax is reduced by 29% in children due de LME ont été recrutés de novembre 2019 à janvier 2022. Les participants
to the presence of a urethral catheter. Males, with an anatomically longer ont rempli le SSVN et d’autres questionnaires (SF-12, ICIQ, SCI-QOL) à
urethra, were particularly affected, with a mean decrease of 7.7 mL/s. l’évaluation initiale et au suivi à 3 mois et 6 mois. La cohérence interne est
Moreover, 13% of children undergoing PFS could not void at all second- évaluée avec le coefficient β de Cronbach et la fiabilité test-retest à l’aide
ary to the presence of the catheter. When using PFS parameters alone, a du coefficient de corrélation intraclasse (CCI). Des corrélations positives ont
clinician may attribute abnormally low flow values to 35% of children été supposées. Une valeur β de 0.70 est considérée acceptable tandis que
assessed, thus abnormally low flow parameters on PFS should be inter- >0.8 est considérée comme bonne. La validité a été évaluée en comparant
preted cautiously. la question qualité de vie avec le questionnaire SF-12.
Résultats : Parmi les 107 participants avec SEP (27) ou LME (80), les
The anti-tumor activity of prebiotics in bladder cancer méthodes de gestion vésicale sont la sonde à demeure (29), le cathétérisme
Jalal Laaraj 1,2,3 , Gabriel Lachance , Amenan Prisca Nadège Kone , Yves intermittent (43), la miction spontanée (24), le condom urinaire (4) et mixte
1,3
1,3
Fradet , Alain Bergeron , Karine Robitaille , Vincent Fradet 1,2,3 (7). À l’évaluation initiale, le score global médian du SSVN était de 24/78
1,2
1,3
1,2
1 Laboratoire d’Uro-Oncologie Expérimentale, Oncology Axis, Centre de (EIQ 15-32.5), similaire à 6 mois (24/78 (EIQ 14-31)). La cohérence interne
recherche du CHU de Québec-Université Laval and Centre de Recherche et la fiabilité test-retest du score global et chaque sous-domaine à 3 mois est
sur le Cancer de l’Université Laval, Quebec, QC, Canada, Faculty of de 0.66 (0.54-0.76), 0,58 pour l’incontinence, 0.73 pour les symptômes de
2
Medicine, Université Laval, Quebec, QC, Canada; Institut sur la nutri- remplissage et 0.58 pour les conséquences. À 6 mois, le résultat global est
3
tion et aliments fonctionnels (INAF) et centre NUTRISS, Université Laval, 0.80 (0.72-0.86) et pour chaque sous-domaine 0.82 (incontinence), 0.82
Quebec, QC, Canada (remplissage) et 0.66 (conséquences). La validité démontre une corrélation
Introduction: Recent evidence showed that gut microbiota plays a crucial statistiquement non significative (p>0.05) à l’évaluation initiale (p=0.217,
role in the response to immune checkpoint blockade (ICB) immunotherapy r=-0.12) et 3 mois (p=0.065, r=-0.12).
in various cancers. Multiple approaches are under investigation to modulate Conclusions : La version franco-canadienne du SSVN démontre une bonne
the gut microbiota and improve the systemic anti-tumor activity of ICB fiabilité ainsi qu’une validité cliniquement significative. Ce questionnaire
in cancer. Here, our objectives were to first assess the anti-tumor effect permet d’évaluer un score global et évaluer chaque sous-domaine des
of promising prebiotics and their modulatory potential on gut microbiota symptômes vésicaux à 3 et 6 mois chez les patients avec SEP et LME. Nous
in bladder cancer (BCa) and then to test the effects of prebiotics on the recommandons son utilisation pour appréciation de la qualité de vie et des
systemic anti-tumor efficacy of ICB therapy. symptômes vésicaux dans une cohorte de patients avec vessie neurogène.
S210 CUAJ • Décembre 2022 • volume 16, numéro 12S3
© 2022 Association des urologues du Canada